Hello. Any danish people invested in Synact? Thought i'd make a short brief of the company.
Synact is a Swedish biotech listed on Nasdaq Stockholm, led by Danish CEO Jeppe Øvlesen and a team of experienced industry professionals.
SynAct Pharma ($SYNACT.ST) is rapidly evolving from a single-asset RA company into a broad inflammation and resolution therapy platform.
At its core is Resomelagon (AP1189), a first-in-class melanocortin agonist that doesn't suppress the immune system but instead actively resolves inflammation. This unique mechanism opens doors across autoimmune, infectious, and acute inflammatory diseases.
Pipeline highlights:
Rheumatoid Arthritis (RA): Phase 2b ADVANCE trial ongoing, targeting early, treatment-naïve patients. Resomelagon could become the first oral, non-steroidal alternative to corticosteroids.
Trigger: Q1 2026
Polymyalgia Rheumatica (PMR): Investigator-led study underway addressing a large unmet need for steroid-sparing therapies.
Trigger: 2026 →
Dengue Fever (RESOVIR-2, Phase II in Brazil): Potential breakthrough in a disease with no effective treatment.
Trigger: 2026→
COVID & viral inflammation: Positive proof-of-concept data supports host-directed anti-inflammatory potential.
TXP platform: Proprietary peptide pipeline (TXP-11, others) broadening SynAct's reach into transplantation and acute immune disorders.
SynAct recently announced a 10M SEK share buyback program, and with strong cash reserves to fund operations well into 2026-2027, plus expected soft funding collaborations in Latin America, the company is in a strong position to accelerate value creation over the coming quarters.
''Last patient in'' announcement should drop in the coming weeks.
Synact is a Swedish biotech listed on Nasdaq Stockholm, led by Danish CEO Jeppe Øvlesen and a team of experienced industry professionals.
SynAct Pharma ($SYNACT.ST) is rapidly evolving from a single-asset RA company into a broad inflammation and resolution therapy platform.
At its core is Resomelagon (AP1189), a first-in-class melanocortin agonist that doesn't suppress the immune system but instead actively resolves inflammation. This unique mechanism opens doors across autoimmune, infectious, and acute inflammatory diseases.
Pipeline highlights:
Rheumatoid Arthritis (RA): Phase 2b ADVANCE trial ongoing, targeting early, treatment-naïve patients. Resomelagon could become the first oral, non-steroidal alternative to corticosteroids.
Trigger: Q1 2026
Polymyalgia Rheumatica (PMR): Investigator-led study underway addressing a large unmet need for steroid-sparing therapies.
Trigger: 2026 →
Dengue Fever (RESOVIR-2, Phase II in Brazil): Potential breakthrough in a disease with no effective treatment.
Trigger: 2026→
COVID & viral inflammation: Positive proof-of-concept data supports host-directed anti-inflammatory potential.
TXP platform: Proprietary peptide pipeline (TXP-11, others) broadening SynAct's reach into transplantation and acute immune disorders.
SynAct recently announced a 10M SEK share buyback program, and with strong cash reserves to fund operations well into 2026-2027, plus expected soft funding collaborations in Latin America, the company is in a strong position to accelerate value creation over the coming quarters.
''Last patient in'' announcement should drop in the coming weeks.
